We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -2.30% | 2.125 | 2.10 | 2.15 | 2.22 | 2.10 | 2.22 | 642,577 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.84 | 7M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2023 08:09 | Results will be a lot sooner than 2027. And yes I work in pharma too. | photon | |
19/6/2023 07:55 | Sell off news no one is hanging around. | johnjames876 | |
19/6/2023 07:46 | Thankfully the markets are forward-looking Nobby. | the imperialist | |
19/6/2023 07:26 | So just to temper enthusiasm I expect we will get the results in early 2027 so approval at the earliest will be in 2028! | nobbygnome | |
19/6/2023 07:12 | This is excellent news. Today should see some significant upside. | manual dexterity | |
19/6/2023 07:11 | So the dosing is ‘at much higher concentrations’ Indeed I wonder if the FDA’s change in stance was down to me. Around 3 years ago I sent an email containing all the documentary evidence to the FDA. I just got a standard reply so of course don’t know if anyone took notice of it but in the interim they completely changed their position. Anyway shareholders should rightly hold McCarthy to account because he was the Chairman at the time….. | nobbygnome | |
16/6/2023 11:50 | It has been said 'no news is good news'; not sure this is true for IMM but as usual it is wait and see. | colsmith | |
16/6/2023 08:49 | Still no news and share price drifts ...really not sure if i should just get out now | lee181067 | |
13/6/2023 13:58 | zilch - it'll be RNS'd. And you can bet your bottom dollar this board will then immediately be drowned in commentary (most of it irrational). | lord loads of lolly | |
13/6/2023 12:33 | any news from the FDA Meeting last week ? | johneee | |
08/6/2023 17:59 | Probably 'cos some expected an RNS the day after their scheduled FDA meeting. To be fair to Tim (& I rarely am, 'cos he's useless), he did say those meeting dates were only estimates and that things could slide. And we're quite used to things sliding at IMM (mainly the share price). | lord loads of lolly | |
08/6/2023 16:46 | Clearly not good as price is going down..but why if no info??? | lee181067 | |
08/6/2023 09:40 | No RNS yet = no update. | lord loads of lolly | |
08/6/2023 09:05 | Has there been any update on the meeting due to take place yesterday | lee181067 | |
02/6/2023 08:48 | Bring on June 7th ----------- Lupazor phase 3 FDA approval meeting If that is positive ........watch this FLY More than Fingers Crossed for everyone | johneee | |
31/5/2023 20:27 | LLOL-see what passes for analysis from him on LSE and weep. | clintdavid1 | |
31/5/2023 15:39 | I see Aridis Pharmaceuticals Inc were up over 170% today - must be to do with this ...... "Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301 ......" | stockriser | |
31/5/2023 15:16 | I've already learnt something, but many thanks for the thought LLOL | stockriser | |
31/5/2023 13:55 | clintdavid1 - yes, then stockriser might actually learn something. | lord loads of lolly | |
31/5/2023 12:33 | You should see what LLOL passes off as analysis! | clintdavid1 | |
30/5/2023 09:28 | You're very welcome LLOL | stockriser | |
30/5/2023 09:27 | Stockriser - thanks for that detailed analysis. | lord loads of lolly | |
30/5/2023 08:46 | Blue today me thinks ;-) GLA SR | stockriser | |
20/5/2023 12:59 | JUNE 7TH DECISION FDA LUPIZOR PHASE 3 TRIALS UNLOCKING $25M AND 70M ROYAL BACK ROYALTIES | purple11 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions